Middle East & Africa Radiopharmaceuticals Market Size & Outlook
Related Markets
MEA radiopharmaceuticals market highlights
- The MEA radiopharmaceuticals market generated a revenue of USD 712.8 million in 2024.
- The market is expected to grow at a CAGR of 10.3% from 2025 to 2030.
- In terms of segment, diagnostics was the largest revenue generating product in 2024.
- Diagnostics is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2025 to 2030.
MEA data book summary
| Market revenue in 2024 | USD 712.8 million |
| Market revenue in 2030 | USD 1,392.7 million |
| Growth rate | 10.3% (CAGR from 2025 to 2030) |
| Largest segment | Diagnostics |
| Fastest growing segment | Diagnostics |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
Other key industry trends
- In terms of revenue, MEA region accounted for 4.0% of the global radiopharmaceuticals market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 7,648.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Radiopharmaceuticals Market Scope
Radiopharmaceuticals Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa radiopharmaceuticals market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to radiopharmaceuticals market will help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of 91.98% in 2024. Horizon Databook has segmented the Middle East & Africa radiopharmaceuticals market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
- Middle East & Africa Radiopharmaceuticals Product Outlook (Revenue, USD Million, 2018-2030)
- Diagnostics
- SPECT
- TC-99m
- TL-201
- GA-67
- I-123
- Others
- PET
- F-18
- SR-82/RB-82
- PYLARIFY (piflufolastat F 18)
- Illuccix (gallium Ga 68 gozetotide)
- Others
- SPECT
- Therapeutics
- Alpha Emitters
- RA-223
- Others
- Beta Emitters
- I-131
- Y-90
- SM-153
- Re-186
- Lu-177
- Others
- Brachytherapy
- Cesium-131
- Iodine-125
- Palladium-103
- Iridium-192
- Others
- Alpha Emitters
- Diagnostics
- Middle East & Africa Radiopharmaceuticals Application Outlook (Revenue, USD Million, 2018-2030)
- Neurology
- Oncology
- Lymphoma
- Endocrine Tumor
- Pulmonary Scans
- Urology
- Other
- Cardiology
- SPECT
- PET
- Therapeutic Applications
- Thyroid
- SPECT
- Therapeutic Applications
- Bone Metastasis
- SPECT
- Therapeutic Applications
- Middle East & Africa Radiopharmaceuticals End Use Outlook (Revenue, USD Million, 2018-2030)
- Hospitals
- Diagnostic Centers
- Others
Reasons to subscribe to Middle East & Africa radiopharmaceuticals market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa radiopharmaceuticals market databook
-
Our clientele includes a mix of radiopharmaceuticals market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa radiopharmaceuticals market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa radiopharmaceuticals market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA radiopharmaceuticals market size, by country, 2018-2030 (US$M)
Middle East & Africa Radiopharmaceuticals Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
